India 'privately' against patent-overriding drug permits

Indian government has "privately reassured" industry lobby group US-India Business Council that the country would not invoke 'compulsory licensing' for commercial purposes that could allow local drugmakers to make cheaper products by overriding patents of big global players.

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the firm to launch copies of two drugs including AstraZeneca Plc`s heartburn pill Nexium, court documents showed.

36 more drugs to be cheaper as govt caps prices

The medicines join the 348 drugs deemed essential and that are therefore subject to price caps.

More medicines to be cheaper as govt planning to extend essential drugs list

Making more drugs subject to price caps will draw the ire of global drugmakers like Pfizer Inc, GlaxoSmithKline Plc and Abbott Laboratories.

US 'not targeting' India, says FDA chief

US regulators are not targeting India, despite a series of import restrictions on drugs from the major US trading partner, the head of the US Food and Drug Administration said today.

Big Pharma pushes for US action against India on drugs

Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

FDA asks Wockhardt to conduct global assessment of its plants

Of late, the FDA has targeted the largest Indian drug manufacturing producers including Ranbaxy.

Govt has little role in controlling prices of patented drugs

Patented drugs are mostly imported and companies have protection under the Patents Act, Minister of State for Chemicals and Fertiliser Srikant Kumar Jena said during Question Hour.